



NEWS RELEASE

# Repligen Completes Expansion of U.S. Manufacturing Facility

2013-11-01

WALTHAM, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met. A dedicated production suite more than doubles capacity for the Company's OPUS<sup>®</sup> line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers.

"This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. "The new cleanroom suite enables us to produce OPUS<sup>®</sup> columns under the highest quality standard demanded by biopharmaceutical manufacturers."

The facility expansion also triples warehouse space and includes dedicated purification and fermentation laboratories for optimization of existing manufacturing processes, new product development and applications support. An additional 17,000 square feet is reserved for future expansion of the same facility, allowing the Company to remain flexible and responsive to the needs of its biopharmaceutical customers and life sciences partners.

## About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a

leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. We also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, we have developed and market our OPUS® line of pre-packed "plug-and-play" chromatography columns, and we provide test kits to ensure final product quality. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, express or implied statements regarding optimization of existing manufacturing process; impact on quality, delivery timing, and GMP compliance; ability to meet customer demands; future expansion of manufacturing facility; and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including without limitation, risks associated with achieving manufacturing optimization, compliance with all regulations including GMP, and other risks detailed in Repligen's Annual Report on Form 10-K on file with the Securities and Exchange Commission and other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward looking statements. These forward looking statements reflect management's current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

CONTACT: Repligen Corporation  
Sondra Newman  
Director Investor Relations  
(781) 419-1881  
snewman@repligen.com

Source: Repligen Corporation